A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naive and Flavivirus-Experienced Health Adults (MK-V181-001-01)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/4/18 → 1/3/21

Funding

  • Merck Sharp & Dohme Corporation ( Award # ): $335,539.45